Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41903611.
- Also identified by DOI 10.1016/j.radonc.2026.111479.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
XXL was a placebo-controlled phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit). Following the unfavorable outcomes of Trilynx [1], XXL the trial was prematurely discontinued after the enrollment of 19 patients and subsequently unblinded; the safety analysis then revealed an increase in treatment-related deaths with xevinapant.